SCHEMBL10180113

SCHEMBL10180113

O=[N+]([O-])c1cc(F)c2c(c1)CCN2

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ADRA2A P08913 5/20 0.44
PNMT P11086 4/20 0.44
ALDH1A1 P00352 3/20 0.40
MAPT P10636 2/20 0.40
CTSL P07711 1/20 0.37
KMT2A Q03164 1/20 0.37
HIF1A Q16665 1/20 0.36
CYP19A1 P11511 1/20 0.35
VCAM1 P19320 1/20 0.34
LMNA P02545 2/20 0.34
HTT P42858 1/20 0.34
NCOA1 Q15788 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
NCOA3 Q9Y6Q9 1/20 0.34
TSHR P16473 1/20 0.33
HTR1D P28221 1/20 0.33
HTR1B P28222 1/20 0.33
ADRA2B P18089 1/20 0.33
ADRA2C P18825 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2675517 0.90 ADRA2A (0.39) ADRA2APNMTALDH1A1MAPTCTSL
SCHEMBL3899701 0.81 CTSL (0.49) ADRA2APNMTALDH1A1MAPTCTSL
SCHEMBL3506059 0.80 ALDH1A1 (0.48) ADRA2APNMTALDH1A1MAPTCTSL
SCHEMBL3920383 0.80 ALDH1A1 (0.50) ADRA2APNMTALDH1A1MAPTCTSL
SCHEMBL14159974 0.80 LMNA (0.46) ADRA2APNMTALDH1A1MAPTCTSL
SCHEMBL3925257 0.80 HTR1D (0.44) ADRA2APNMTALDH1A1MAPTCTSL
SCHEMBL2675271 0.78 KIF11 (0.42) ADRA2APNMTALDH1A1KMT2AHIF1A
SCHEMBL9470708 0.76 MAPT (0.43) ADRA2APNMTALDH1A1MAPTCTSL
SCHEMBL2261586 0.72 PARP10 (0.39)
SCHEMBL1163368 0.72 TDP2 (0.51) ADRA2APNMTALDH1A1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4551571-A1 OXAZOLE TRPML1 AGONISTS AND USES THEREOF Libra Therapeutics, Inc. (US) 2025-05-14 EP disclosed
CN-119790050-A Oxazole TRPML1 agonists and uses thereof 利布拉医疗公司 2025-04-08 CN disclosed
US-12098145-B2 Oxazole TRPML1 agonists and uses thereof LIBRA THERAPEUTICS, INC. (US) 2024-09-24 US disclosed
US-20240158381-A1 OXAZOLE TRPML1 AGONISTS AND USES THEREOF LIBRA THERAPEUTICS, INC. 2024-05-16 US disclosed
WO-2024011155-A1 OXAZOLE TRPML1 AGONISTS AND USES THEREOF LIBRA THERAPEUTICS, INC. (US) 2024-01-11 WO disclosed
WO-2017153952-A1 5-SULFAMOYL-2-HYDROXYBENZAMIDE DERIVATIVES GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2017-09-14 WO disclosed
CN-102971304-A GPR119 agonists NIPPON CHEMIPHAR CO 2013-03-13 CN disclosed
US-20120245344-A1 GPR119 AGONIST NIPPON CHEMIPHAR CO., LTD. (JP) 2012-09-27 US disclosed
EP-2474540-A1 GPR119 AGONIST Nippon Chemiphar Co., Ltd. (JP) 2012-07-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12098145-B2 Oxazole TRPML1 agonists and uses thereof TRPM7, TRPM2, TRPM5 ADRA2A 476/4885PNMT 3318/4885ALDH1A1 1854/4885
US-20240158381-A1 OXAZOLE TRPML1 AGONISTS AND USES THEREOF TRPM7, TRPM2, TRPM5 ADRA2A 1125/4885PNMT 3447/4885ALDH1A1 2066/4885
US-20120245344-A1 GPR119 AGONIST GPR119, GPR4, GPR55 ADRA2A 64/4885PNMT 3261/4885ALDH1A1 2871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.